In the dynamic field of pharmaceutical research and development, securing reliable access to high-quality chemical intermediates is paramount, especially when tackling critical health issues like antibiotic resistance. Avibactam Intermediates, such as the compound identified by CAS number 1174020-25-7, are fundamental to creating advanced antibacterial solutions. Ningbo Inno Pharmchem Co., Ltd. is committed to being a trusted supplier of these essential materials.

The Avibactam Intermediate, CAS 1174020-25-7, is a key precursor in the synthesis of avibactam. Avibactam is a vital beta-lactamase inhibitor that plays a crucial role in combination therapies, restoring the efficacy of antibiotics against bacteria that have developed resistance mechanisms. The meticulous synthesis and purification of this intermediate ensure that pharmaceutical manufacturers can produce avibactam with the high purity and consistent quality required for clinical applications. Ningbo Inno Pharmchem Co., Ltd. ensures that all intermediates meet stringent quality control measures, including certifications like GMP and ISO 9001.

For pharmaceutical companies looking to innovate and expand their portfolio of treatments for challenging infections, sourcing reliable Avibactam Intermediates is a strategic decision. These intermediates empower researchers and manufacturers to develop next-generation antibiotics, addressing unmet medical needs. By providing not just the chemical compound but also comprehensive support, Ningbo Inno Pharmchem Co., Ltd. aims to be a proactive partner in the drug development process. Understanding the precise chemical properties and applications of CAS 1174020-25-7 allows for more efficient and effective drug design.

The ongoing fight against antibiotic resistance necessitates continuous innovation. By supplying critical components like the Avibactam Intermediate, Ningbo Inno Pharmchem Co., Ltd. contributes directly to the advancement of global health. We are dedicated to supporting our clients in their efforts to bring effective and safe antibacterial therapies to market, thereby making a significant impact on patient outcomes worldwide.